MLANA and neoplasm: Based on this background, we have explored the possibility of constructing innovative vaccine formulations for clinical tumour immunotherapy, by taking advantage of well-described (Kawakami et al, 1994; Valmori et al, 1998) HLA-A2.1-restricted peptides from the immunodominant Melan-A/MART-1 melanoma TAA and liposome technology.